XG-005 is under clinical development by Xgene Pharmaceutical and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XG-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XG-005 is under development for the treatment of acute and chronic pain including post operative pain, low back pain, traumatic pain, painful knee osteoarthritis. The drug candidate is a conjugate of naproxen and pregabalin. It is administered through oral route as a tablet and capsule. Naproxen acts by targeting COX1 and COX2 whereas pregabalin acts by targeting voltage dependent calcium channel subunit alpha2/delta1 and delta 2. It was also under development for arthritis pain and chronic pain in chemotherapy induced peripheral neuropathy.
Xgene Pharmaceutical overview
Xgene Pharmaceutical is a clinical stage healthcare and pharmaceutical company. The company pipeline product include XG005-02, XG005-03, XG004-03 and XG043 among others. It’s XG005-02 products is in US Phase III studies in treatment of acute pain. The company discovers and develops novel small-molecule drugs for chronic pain, tumors and infectious diseases. Xgene Pharmaceutical serves its product in gels, oral tablets and others. Xgene Pharmaceutical also invests in drug development programs targeting acute, chronic pain, cluster headache, dizziness, sleeplessness, confusion and others. The company operates in Taiwan and China. Xgene Pharmaceutical is headquartered in Jing An, Shanghai, China.
For a complete picture of XG-005’s drug-specific PTSR and LoA scores, buy the report here.